USD 13.52 million received! Abbisko Therapeutics has received a milestone payment from Merck triggered by the first prescription of Bejime® in China, as well as Q1 2026 sales royalties.

On June 9, 2026, Shanghai Abbisko Therapeutics Co., Ltd. (hereinafter referred to as 'Abbisko Therapeutics,' HKEX: 2256) announced today thatthe company has received a USD 13.52 million payment from Merck。This amount includes the milestone payment triggered by the first prescription of Pemigatinib Hydrochloride Capsules (Pemazyre®) in China, as well as the sales royalty for the first quarter of 2026.and will be recognized as part of the company's revenue for fiscal year 2026.$ABBISKO-B (02256.HK)$

In December 2023, Abbisko Therapeutics entered into an exclusive licensing agreement with Merck for Pemazyre®, with a potential total deal value of up to USD 605.5 million, comprising upfront payments, development and commercialization milestone payments, and double-digit royalties on global annual net sales of pemigatinib. Previously, Abbisko Therapeutics had already received a total of USD 155 million in upfront and option exercise fees in 2024 and 2025, while Merck obtained exclusive global commercialization rights to Pemazyre®.

Since the collaboration began, both parties have advanced the project efficiently and smoothly. In December 2025, just over six months after China’s National Medical Products Administration (NMPA) accepted the first global New Drug Application for Pemazyre®, it received approval without any request for supplementary information ('zero deficiency letter'), becoming China’s first and currently only approved Class 1 innovative drug for the treatment of tenosynovial giant cell tumor (TGCT). In March 2026, the world’s first prescription of Pemazyre® was issued at Beijing Jishuitan Hospital, addressing the long-unmet need for systemic therapy among Chinese TGCT patients.

$ABBISKO-B (02256.HK)$

15K Views